ATE260337T1 - Neue oligomere konjugate zum transfer biologischer moleküle in zellen - Google Patents
Neue oligomere konjugate zum transfer biologischer moleküle in zellenInfo
- Publication number
- ATE260337T1 ATE260337T1 AT99959296T AT99959296T ATE260337T1 AT E260337 T1 ATE260337 T1 AT E260337T1 AT 99959296 T AT99959296 T AT 99959296T AT 99959296 T AT99959296 T AT 99959296T AT E260337 T1 ATE260337 T1 AT E260337T1
- Authority
- AT
- Austria
- Prior art keywords
- cells
- transfer
- biological molecules
- oligomeric conjugates
- new oligomeric
- Prior art date
Links
- 238000006116 polymerization reaction Methods 0.000 abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polyamides (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98403015 | 1998-12-02 | ||
| PCT/EP1999/008980 WO2000032764A1 (en) | 1998-12-02 | 1999-11-22 | New oligomeric conjugates liable to transfer biological molecules into cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE260337T1 true ATE260337T1 (de) | 2004-03-15 |
Family
ID=8235574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99959296T ATE260337T1 (de) | 1998-12-02 | 1999-11-22 | Neue oligomere konjugate zum transfer biologischer moleküle in zellen |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1135481B1 (de) |
| JP (1) | JP2002532388A (de) |
| AT (1) | ATE260337T1 (de) |
| AU (1) | AU770963B2 (de) |
| CA (1) | CA2348823A1 (de) |
| DE (1) | DE69915103T2 (de) |
| ES (1) | ES2213397T3 (de) |
| WO (1) | WO2000032764A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7070807B2 (en) | 1999-12-29 | 2006-07-04 | Mixson A James | Branched histidine copolymers and methods for using same |
| CA2394758A1 (en) | 1999-12-29 | 2001-07-05 | A. James Mixson | Histidine-containing copolymers enhance pharmaceutical agent delivery |
| US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
| DK1301213T3 (en) * | 2000-07-21 | 2017-03-27 | Revance Therapeutics Inc | MULTI-COMPONENT SYSTEMS FOR BIOLOGICAL TRANSPORT |
| WO2003066054A1 (en) * | 2002-02-01 | 2003-08-14 | Intradigm Corporation | Cationic polymers for use in therapeutic agent delivery |
| US7465708B2 (en) | 2002-11-25 | 2008-12-16 | Mixson A James | Branched cationic copolymers and methods for antimicrobial use |
| US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| BRPI0508440A (pt) | 2004-03-03 | 2007-07-24 | Revance Therapeutics Inc | composições e métodos para diagnóstico tópico e transporte terapêutico |
| ES2362301T3 (es) | 2005-03-03 | 2011-07-01 | Revance Therapeutics, Inc. | Composiciones y procedimientos para aplicaciones tópicas y liberación transdérmica de un oligopéptido. |
| KR20070110402A (ko) | 2005-03-03 | 2007-11-16 | 레반스 테라퓨틱스 | 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및방법 |
| FR2928373B1 (fr) | 2008-03-05 | 2010-12-31 | Centre Nat Rech Scient | Polymere derive de la polyethylenimine lineaire pour le transfert de gene. |
| CA2889044A1 (en) | 2012-11-15 | 2014-05-22 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| WO2015078995A1 (en) * | 2013-11-28 | 2015-06-04 | Institut National de la Santé et de la Recherche Médicale | Agents for treating cystic fibrosis |
| CN114716518A (zh) * | 2021-01-06 | 2022-07-08 | 圣诺制药公司 | 一种能够抑制pcsk9表达的分子构造及药物组合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5627270A (en) * | 1991-12-13 | 1997-05-06 | Trustees Of Princeton University | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same |
| WO1994001550A1 (en) * | 1992-07-02 | 1994-01-20 | Hybridon, Inc. | Self-stabilized oligonucleotides as therapeutic agents |
| US5656609A (en) * | 1992-09-24 | 1997-08-12 | University Of Connecticut | Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine |
| KR100324257B1 (ko) * | 1993-09-28 | 2002-08-27 | 히사미쓰 세이야꾸 가부시키가이샤 | 폴리아미노산올리고뉴크레오타이드운반체 |
| GB9623051D0 (en) * | 1996-11-06 | 1997-01-08 | Schacht Etienne H | Delivery of DNA to target cells in biological systems |
| FR2755976B1 (fr) * | 1996-11-15 | 1999-01-15 | Idm Immuno Designed Molecules | Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires |
-
1999
- 1999-11-22 ES ES99959296T patent/ES2213397T3/es not_active Expired - Lifetime
- 1999-11-22 DE DE69915103T patent/DE69915103T2/de not_active Expired - Fee Related
- 1999-11-22 AT AT99959296T patent/ATE260337T1/de not_active IP Right Cessation
- 1999-11-22 AU AU16526/00A patent/AU770963B2/en not_active Ceased
- 1999-11-22 CA CA002348823A patent/CA2348823A1/en not_active Abandoned
- 1999-11-22 WO PCT/EP1999/008980 patent/WO2000032764A1/en not_active Ceased
- 1999-11-22 EP EP99959296A patent/EP1135481B1/de not_active Expired - Lifetime
- 1999-11-22 JP JP2000585395A patent/JP2002532388A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU1652600A (en) | 2000-06-19 |
| ES2213397T3 (es) | 2004-08-16 |
| JP2002532388A (ja) | 2002-10-02 |
| WO2000032764A1 (en) | 2000-06-08 |
| EP1135481B1 (de) | 2004-02-25 |
| DE69915103T2 (de) | 2004-12-09 |
| EP1135481A1 (de) | 2001-09-26 |
| DE69915103D1 (de) | 2004-04-01 |
| CA2348823A1 (en) | 2000-06-08 |
| AU770963B2 (en) | 2004-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69915103D1 (de) | Neue oligomere konjugate zum transfer biologischer moleküle in zellen | |
| DE50006269D1 (de) | Kombinationen zur einführung von nucleinsäuren in zellen | |
| ATE281468T1 (de) | Multifunktionelle molekuläre komplexe für den gen-transfer in zellen | |
| DE69637256D1 (de) | Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle | |
| ATE174599T1 (de) | Bindungskompetente oligomere, die 2',5'-bindungen enthalten | |
| BR9808154A (pt) | Moléculas de ácido nucléico codificando enzimas tendo atividade de frutosil polimerase | |
| DE69602138D1 (de) | Polymerisation in gegenwart von einem beta-substituiertem nitroxyd-radikal | |
| DK0524997T3 (da) | 2-O-alkylnukleotider samt polymerer, som indeholder sådanne nukleotider | |
| BR9711117A (pt) | Oligossacarídios modificados. | |
| EP1862472A3 (de) | Chlamydia-Protein, Gensequenz und Verwendung | |
| EA200100365A1 (ru) | Синтазы | |
| BR0211200A (pt) | Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células | |
| EP0631623A4 (de) | Dna kodierend für taurin und gaba transportern und ihre verwendungen. | |
| FR2755976B1 (fr) | Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires | |
| HUP9802157A2 (hu) | Biológiailag összeférhető kis molekulatömegű poli(etilén-imin)-ek | |
| CY1106041T1 (el) | Καινοφανης συλλεκτινη | |
| IL111601A0 (en) | Conjugate comprising a targetting molecule, dna or rna encoding it, vector and cell ling containing said dna or rna | |
| PL336000A1 (en) | Cosmetic compositions containing a cationic polymer of low molecular weight and a silicone as well as their application | |
| ATE195320T1 (de) | Neue polymerträger zur nukleinsäuresynthese | |
| BR0008785A (pt) | Variantes de polipeptìdeo com capacidade aumentada de ligação com a heparina | |
| DE59506963D1 (de) | Medizinischer haftkleber | |
| DK1179537T3 (da) | Fastfasepeptidsyntesefremgangsmåde | |
| WO1997049718A3 (fr) | Conjugues d'un oligonucleotide/polymere conducteur electronique avec une molecule d'interet, et leurs utilisations | |
| HUT77029A (hu) | A GAP-protein SH3 doménjéhez kötődni képes peptidek, ezeket kódoló nukleotidszekvenciák és előállításuk és alkalmazásuk | |
| RU96106897A (ru) | Рецептор глюканового активатора и кодирующая его молекула днк |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |